Crearene AG and Alzchem Group AG Report Success in Creatine Dialysis Treatment Study

Alzchem Group AG and Crearene AG, through a collaborative effort, have announced positive initial results from their clinical trial involving the use of creatine in dialysis patient treatments. Initiated in October 2023, the study aimed at assessing the technical implementation, safety for patients, and optimal dosing for creatine-based dialysis solutions. Conducted at the University Medical Center Groningen under Prof. Dr. Stephan J.L. Bakker, the study utilized a double-blind method across four different patient groups to ensure rigor.

The results highlighted the feasibility of administering creatine during hemodialysis, confirming its tolerance in patients with end-stage chronic kidney disease and providing valuable dose-response data. While the efficacy outcomes appear promising, detailed results are anticipated by the summer of 2024. This study's promising initial findings have led to both entities extending their partnership to develop creatine-based medical treatments until the end of 2025, aiming to enhance the treatment for over three million dialysis patients globally.